Business
AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids
AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids\r\n \r\n \r\n\r\n\r\nAXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter Into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids\r\n\r\n\r\n\r\n\r\n\r\nSAN DIEGO, CA - January 29, 2026 (NEWMEDIAWIRE) - AXIM Biotechnologies, Inc. (OTC: AXIM) (the \"Company\") today announced a strategic alliance with Medical Marijuana, Inc. (OTC: MJNA) intended to research and develop applications and uses for AXIM's patent for water soluble cannabinoids.\r\nAt the center of the transactions entered into between the Company and MJNA is AXIM's U.S. Patent No. 11,542,226 B2, Polyfunctional Cannabinoids (the \"Patent\"). AXIM assigned to MJNA a fifty percent (50%) right, title, and economic interest in the Patent and all associated intellectual property. The assignment includes rights to:\r\n\r\n Existing and future U.S. and foreign patents and applications\r\n Licensing, enforcement, and monetization proceeds\r\n Claims for past infringement and accrued royalties\r\n \r\n Concurrently, with the Patent assignment, AXIM and MJNA entered into a Consulting Agreement, whereby the Company will provide MJNA with research and development services focused on researching and developing applications and uses for the Patent technology.\r\nCatalina Valenica, AXIM President, in commenting on the transactions stated: \"This alliance with MJNA presents both companies with the ability to accelerate uses of the Patent technology. The water solubility of CBD and other cannabinoids is a significant development for the improved administration and increased potency of cannabinoids. We believe that the Patent could result in the development of a drug or treatment, most likely in the form of sublingual administration, able to treat a variety of conditions including anxiety or seizures. We are very excited about this new partnership and the potential it can unlock for our respective companies.\"\r\nDr. Scott, MJNA Chairman and President, stated: \"We have tremendous confidence in the AXIM team's ability to provide R&D support for the development of commercialized uses of the Patent technology. ...